People looking for a booster shot of a Covid-19 vaccine probably don’t need to fret about what brand it is: Many combinations of shots are likely to provide strong protection, according to a large new study.

In a comparison of seven different vaccine brands, British researchers found that most of them prompted a strong immune response, with the mRNA shots from Moderna and Pfizer-BioNTech eliciting the largest responses. The study was published on Thursday in The Lancet.

Continue reading “Most Covid Vaccines Will Work as Boosters, Study Suggests” →

A federal advisory committee on Tuesday voted to recommend that the government for the first time authorize the use of an antiviral pill to combat the worst effects of Covid-19.

The advisory committee, in a surprisingly narrow 13-to-10 vote, endorsed the pill from Merck, while public health officials worldwide raced to buttress their defenses against the newly emerging Omicron variant of the coronavirus.

The Merck treatment, known as molnupiravir, has been shown to modestly reduce the risk of hospitalization and death from Covid. The pill could be authorized for use in the United States within days and available to patients within weeks.

Continue reading “Merck’s Covid Treatment Pill Wins Blessing of F.D.A. Panel” →

Scientific experts at the World Health Organization warned on Friday that a new coronavirus variant discovered in southern Africa was a “variant of concern,” the most serious category the agency uses for such tracking.

The designation, announced after an emergency meeting of the health body, is reserved for dangerous variants that may spread quickly, cause severe disease or decrease the effectiveness of vaccines or treatments. The last coronavirus variant to receive this label was Delta, which took off this summer and now accounts for virtually all Covid cases in the United States.

The W.H.O. said the new version, named Omicron, carries a number of genetic mutations that may allow it to spread quickly, perhaps even among the vaccinated.

Continue reading “New Virus Variant Stokes Concern but Vaccines Still Likely to Work” →

A scientist who has pored over public accounts of early Covid-19 cases in China reported on Thursday that an influential World Health Organization inquiry had most likely gotten the early chronology of the pandemic wrong. The new analysis suggests that the first known patient sickened with the coronavirus was a vendor in a large Wuhan animal market, not an accountant who lived many miles from it.

The report, published on Thursday in the prestigious journal Science, will revive, though certainly not settle, the debate over whether the pandemic started with a spillover from wildlife sold at the market, a leak from a Wuhan virology lab or some other way. The search for the origins of the greatest public health catastrophe in a century has fueled geopolitical battles, with few new facts emerging in recent months to resolve the question.

Continue reading “First Known Covid Case Was Vendor at Wuhan Market, Scientist Says” →

Novavax, a Maryland-based company that received $1.75 billion from the United States government to develop a protein-based Covid-19 vaccine, announced Monday it had won emergency authorization for its vaccine in Indonesia.

After months of production delays, this is the first authorization for Novavax and its manufacturing partner, the Serum Institute of India. They have also applied for clearance in India and the Philippines, and Novavax has applied on its own to other countries, including Britain and Canada.

Continue reading “The Novavax vaccine, backed by Operation Warp Speed, has won its first authorization — in Indonesia.” →